![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Alkermes Submits NDA for Vivitrex to Treat Alcohol Dependence
Alkermes Submits NDA for Vivitrex to Treat Alcohol Dependence
Alkermes has submitted a new drug application (NDA) to the FDA for marketing approval of Vivitrex, an investigational drug in development for the treatment of alcohol dependence.
If approved, Vivitrex (naltrexone long-acting injection) would be the first medication available for the treatment of alcohol dependence in a formulation that is administered once-monthly by injection, the company said.
Vivitrex, an injectable, long-acting formulation of the currently approved drug naltrexone, was designed utilizing Alkermes' proprietary Medisorb drug-delivery technology. Using the Medisorb technology, naltrexone is encapsulated in microspheres made of a biodegradable polymer that dissolve slowly and release the drug at a controlled rate following intramuscular injection.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
11Jul
-
18Jul
-
21Oct